News Feed Item

Orphan Drugs Market 2018 Outlook and Pipeline Analysis

DALLAS, March 22, 2014 /PRNewswire/ --

ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug Pipeline Analysis" research reports in its store.

The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs. The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market says the report Global  Orphan  Drug  Market  Outlook  2018 available at http://www.reportsnreports.com/reports/274449-global-orphan-drug-market-outlook-2018.html . This research is available at 20% discount on all user types till March 31, 2014.

The orphan drugs enjoy significant competitive advantages in the market owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs.

"Global  Orphan  Drug  Market  Outlook  2018"  research  report  provides  comprehensive  insights  on  following  developments  related  to  global  orphan  drug  market: Global & Regional Orphan Drug Market Overview, Orphan Drug Designation Criteria Across Key Markets, Market Specific Reimbursement Policy & Regulatory Framework, Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country and Competitive Landscape talking about Pfizer, Roche, Sanofi, Rare Disease Therapeutics, Glaxosmithkline, Merck, Novartis Pharmaceuticals, Alexion, Celgene, Biogen Idec, Eli Lilly and Bristol Myers Squibb. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=274449 .

The report titled Global  Orphan  Drugs  Market  2014-2018 forecasts the industry to grow at 5.67% to 2018. has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the Americas, and the EMEA and APAC regions; it also covers the Global Orphan Drugs market landscape and its growth prospects in the coming years. The report (http://www.reportsnreports.com/reports/274574-global-orphan-drugs-market-2014-2018.html ) also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space are Novartis AG, F. Hoffmann-La Roche Ltd., Celgene Corp., Pfizer Inc., and Sanofi S.A. Other vendors mentioned in the report are Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Biogen Idec Inc., Bristol-Myers-Squibb Co., GlaxoSmithKline plc, Eli Lilly & Co., Merck KGaA, Novo Nordisk A/S, Onyx Pharmaceuticals Inc., Shire plc, and Vertex Pharmaceuticals Inc. Order a copy of Global  Orphan  Drugs  Market  2014-2018 research report at http://www.reportsnreports.com/Purchase.aspx?name=274574 .

In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry. With close to 65-70 Million people in the US & Europe having some kind of rare disease complaints, the increasing activities around the development of orphan drugs only imply that the appropriate treatments for unmet needs are increasing, thus increasing the profit margins in the future. As the Asian pharmaceutical markets are still in growth stage, the opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2020, the Asian orphan drugs market would witness steady growth.

The report Global  Orphan  Drug  Pipeline  Analysis gives comprehensive insight on the various orphan designated drugs being developed for the treatment of rare disease. Research report covers all the orphan designated drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Orphan Drug market based upon development process.

Following  parameters  for  each  orphan  designated  drug  profile  in  development  phase  are  covered  in  "Global  Orphan  Drug  Pipeline  Analysis"  research  report  available  athttp://www.reportsnreports.com/reports/271801-global-orphan-drug-pipeline-analysis.html  :

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

Global  Orphan  Drug  Pipeline  by  Clinical  Phase:

  • Research: 3
  • Preclinical: 71
  • Clinical: 4
  • Phase-I: 61
  • Phase-I/II: 71
  • Phase-II: 198
  • Phase-II/III: 20
  • Phase-III: 103
  • Preregistration: 26
  • Registration: 17
  • Marketed: 244
  • Unknown: 1

Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=271801. This report is available at 20% discount till March 31, 2014 on all user types.

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About  Us:

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]

Connect  With  Us  on:

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports
Pinterest: www.pinterest.com/comeonseo/reportsnreports/

SOURCE ReportsnReports.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Enterprises have been using both Big Data and virtualization for years. Until recently, however, most enterprises have not combined the two. Big Data's demands for higher levels of performance, the ability to control quality-of-service (QoS), and the ability to adhere to SLAs have kept it on bare metal, apart from the modern data center cloud. With recent technology innovations, we've seen the advantages of bare metal erode to such a degree that the enhanced flexibility and reduced costs that cl...
19th Cloud Expo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterpri...
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, will discuss how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team a...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and microservices. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your conta...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Established in 1998, Calsoft is a leading software product engineering Services Company specializing in Storage, Networking, Virtualization and Cloud business verticals. Calsoft provides End-to-End Product Development, Quality Assurance Sustenance, Solution Engineering and Professional Services expertise to assist customers in achieving their product development and business goals. The company's deep domain knowledge of Storage, Virtualization, Networking and Cloud verticals helps in delivering ...
Intelligent machines are here. Robots, self-driving cars, drones, bots and many IoT devices are becoming smarter with Machine Learning. In her session at @ThingsExpo, Sudha Jamthe, CEO of IoTDisruptions.com, will discuss the next wave of business disruption at the junction of IoT and AI, impacting many industries and set to change our lives, work and world as we know it.
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, will discuss how Numerex, as an experienced, established IoT provider, has embraced a ...
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Today every business relies on software to drive the innovation necessary for a competitive edge in the Application Economy. This is why collaboration between development and operations, or DevOps, has become IT’s number one priority. Whether you are in Dev or Ops, understanding how to implement a DevOps strategy can deliver faster development cycles, improved software quality, reduced deployment times and overall better experiences for your customers.
Cloud based infrastructure deployment is becoming more and more appealing to customers, from Fortune 500 companies to SMEs due to its pay-as-you-go model. Enterprise storage vendors are able to reach out to these customers by integrating in cloud based deployments; this needs adaptability and interoperability of the products confirming to cloud standards such as OpenStack, CloudStack, or Azure. As compared to off the shelf commodity storage, enterprise storages by its reliability, high-availabil...